

HOTLINE: Effective February 22, 2022

New Test

3004437

Multiple Endocrine Neoplasia Type 1 (MENI) Sequencing and

MEN1 NGS

Deletion/Duplication



Patient History for Multiple Endocrine Neoplasia Type 1 (MEN1) Testing



Additional Technical Information

Methodology: Massively Parallel Sequencing

Performed: Varies **Reported:** 3 weeks

Specimen Required: Collect: Lavender or Pink (EDTA) or Yellow (ACD Solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 3 mL)

Storage/Transport Temperature: Refrigerated.

<u>Unacceptable Conditions:</u> Serum or plasma; grossly hemolyzed or frozen specimens; saliva; buccal brush or swab, FFPE tissue.

Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval: By report

Interpretive Data:

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: Gene Tested: MEN1 (NM_130799)

CPT Code(s): 81404, 81405

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.